Skip to main content

Table 5 Comparison between AML subgroups regarding demographic, clinical data and hematological parameters at diagnosis

From: Methyltransferase-like 3 gene (METTL3) expression and prognostic impact in acute myeloid leukemia patients

Demographic data, clinical data and hematological data Non-responder AML cases with high normalized METTL3 gene expression (n = 25) Responder AML cases with low normalized METTL3 gene expression (n = 15) Significance
Test p value
Gender
 Female 13 (52.0%) 5 (33.3%) χ2 = 1.320 0.251
 Male 12 (48.0%) 10 (66.7%)   
HSM
 Yes 23 (92.0%) 9 (60.0%) χ2 = 6.000 0.014*
 No 2 (8.0%) 6 (40.0%)   
Age (years)
 Mean ± SD 43.20 ± 18.44 39.80 ± 16.31 t = 0.347 0.560
 Range 18–76 20–63
TLC
 Median (IQR) 40 (1.9–70) 31.9 (2–75) z = 1.681 0.203
HB
 Mean ± SD 7.69 ± 1.45 6.84 ± 1.81 t = 2.665 0.111
 Range 4.00–10.4 3.30–9   
PLTs
 Median (IQR) 19 (12–89) 34 (11–55) z = 2.446 0.126
BM blasts%
 Median (IQR) 75 (72–85) 85 (48–88) z = 2.124 0.153
  1. HSM hepatosplenomegaly, TLC total leucocyte count, HB hemoglobin, PLTs platelets, χ2 Chi-square test, t independent sample t test, z Mann–Whitney test
  2. *p value < 0.05 S; p value > 0.05 NS
  3. Bold value is the only statistically significant p value = 0.014